Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | PTPRC | P08575 | 2/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | S100A4 | P26447 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14565383 | 0.86 | TSHR (0.60) | CYP3A4TSHRTDP1ALDH1A1CYP19A1 | |
| SCHEMBL10487196 | 0.84 | CYP3A4 (0.64) | CYP3A4TSHRTDP1ALDH1A1PTPRC | |
| SCHEMBL14746480 | 0.81 | HSD17B10 (0.53) | CYP3A4TSHRTDP1ALDH1A1CYP19A1 | |
| SCHEMBL29214106 | 0.81 | PTPRC (0.54) | CYP3A4TSHRTDP1ALDH1A1PTPRC | |
| SCHEMBL28069343 | 0.79 | CYP19A1 (0.54) | CYP3A4TSHRTDP1ALDH1A1CYP19A1 | |
| SCHEMBL27928935 | 0.78 | PTPRC (0.47) | CYP3A4TSHRTDP1ALDH1A1PTPRC | |
| SCHEMBL3120559 | 0.78 | RAB9A (0.58) | CYP3A4TSHRTDP1ALDH1A1PTPRC | |
| SCHEMBL27493562 | 0.77 | MYC (0.53) | CYP3A4TDP1ALDH1A1CYP19A1PTPRC | |
| SCHEMBL4437873 | 0.77 | CYP3A4 (1.00) | CYP3A4TSHRTDP1ALDH1A1ACHE | |
| SCHEMBL2313 | 0.77 | CYP3A4 (1.00) | CYP3A4TSHRTDP1ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171419-B1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6552088-B2 | 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor | HOFFMANN-LA ROCHE INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020040060-A1 | Biphenyl derivatives | BOS MICHAEL (CA) | 2002-04-04 | — | — | US | disclosed |
| EP-1171419-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6291465-B1 | Biphenyl derivatives | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000053572-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040060-A1 | Biphenyl derivatives | NR1H4, NR1H2, NR1H3 | CYP3A4 532/4885TSHR 146/4885TDP1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.